Abstract Details

Title Identification of New Biomarkers in Diabetic Distal Symmetrical Polyneuropathy with Conduction Slowing: A Prospective Proteomics Analysis

Topic Neuromuscular and Clinical Neurophysiology (EMG)

Presentation(s) P8 - Poster Session 8 (5:30 PM-6:30 PM)

Poster/Presentation
Number 11-003

Objective To identify new biomarkers of diabetic distal symmetrical polyneuropathy (DDSP) with conduction slowing.

Background DDSP is associated with conduction slowing more than would be expected solely from large fiber axon loss.

Design/Methods We collected serum samples from 10 persons- 5 healthy controls (HC) and 5 patients with DDSP with conduction slowing (DNCS). The samples were processed and labeled by TMT and then were analyzed by nano LC-MS/MS on an Orbitrap Fusion Lumos Mass Spectrometer using the MS2 method. The protein extracts were run through LC-MS/MS on Oribtrap Velos MS instrument for subsequent data analysis. The MS/MS spectra were searched against the UniProt human database using the Sequest search engine on Proteome Discoverer (V2.4) platform. The relative protein abundance was calculated based on spectrum counting.

Results The DDSP patients’ average Overall Neuropathy Limitations Scale (ONLS), Rasch-Built Overall Disability Scale (R-ODS), Total Neuropathy Score, and HBA1C were 2.8, 32.4, 18.8, and 7.75% respectively. A total of 1,226 protein groups were identified of which 95 proteins were found significantly changed in the ratio of DNCS/HC. The ratio of DNCS/HC protein was significantly increased in 53 proteins (ratio>1, P<0.05) and decreased in 42 proteins (ratio<1, P<0.05)

Conclusions Proteomics analysis is a useful, high-throughput method for screening biomarkers that indicated impairment in nerve conduction in DDSP. Future studies will include DDSP without conduction slowing, diabetic patients without neuropathy and CIDP patients. The goal is to identify specific biomarkers for early diagnosis and prognosis of DDSP including DDSP with conduction slowing consistent with demyelination

Authors/Disclosures
Kazim Jaffry PRESENTER	Mr. Jaffry has nothing to disclose.
Kelly Saverino (Rutgers University)	Miss Saverino has nothing to disclose.
Joseph Wardell	No disclosure on file
Belinda Philip, MBBS (Rutgers - The State University of New Jersey)	Dr. Philip has nothing to disclose.
Ankit Pahwa	Ankit Pahwa has nothing to disclose.
Daniel L. Menkes, MD, FAAN (Neuroscience Center)	An immediate family member of Dr. Menkes has received personal compensation for serving as an employee of NIH. An immediate family member of Dr. Menkes has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for CMTE. An immediate family member of Dr. Menkes has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for NIH. Dr. Menkes has received personal compensation in the range of $100,000-$499,999 for serving as an Expert Witness for Self Employed. An immediate family member of Dr. Menkes has received research support from Helmsley Foundation . An immediate family member of Dr. Menkes has received intellectual property interests from a discovery or technology relating to health care.
Zhao Zhong Chong	Zhao Zhong Chong has nothing to disclose.
Nizar Souayah, MD, FAAN (NJMS)	Dr. Souayah has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Takeda. Dr. Souayah has received publishing royalties from a publication relating to health care.

��ɫ��

��ɫ��